| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439490 | European Journal of Cancer | 2018 | 10 Pages |
Abstract
A significant proportion of AYAs with advanced cancer have targetable somatic or germline mutations. Consideration of familial risk factors and inclusion of germline testing wherever appropriate can complement tumour testing to optimise patient management and inform management of at-risk relatives.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B. Kaye, Udai Banerji, Juanita S. Lopez, Johann de Bono, Winette T.A. van der Graaf, Angela J. George,